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ABSTRACT 
Tumor-mobilized bone marrow-derived CD11b+ myeloid cells promote tumor 
angiogenesis, but how and when these cells acquire proangiogenic properties is not 
fully elucidated. Here we show that CD11b+ myelomonocytic cells develop 
proangiogenic properties during their differentiation from CD34+ hematopoietic 
progenitors and that Placenta Growth Factor (PlGF) is critical in promoting this 
education. Cultures of human CD34+ progenitors supplemented with conditioned 
medium from breast cancer cell lines or PlGF, but not from non-tumorigenic breast 
epithelial lines, generate CD11b+ cells capable of inducing endothelial cell sprouting 
in vitro and angiogenesis in vivo. An anti-Flt-1 mAb or soluble Flt-1 abolished the 
generation of proangiogenic activity during differentiation from progenitors cells. 
Moreover, inhibition of metalloproteinase activity, but not VEGF, during the 
endothelial sprouting assay blocked sprouting induced by these proangiogenic 
CD11b+ myelomonocytes. In a mouse model of breast cancer, circulating CD11b+ 
cells were proangiogenic in the sprouting assays. Silencing of PlGF in tumor cells 
prevented the generation of proangiogenic activity in circulating CD11b+ cells, 
inhibited tumor blood flow and slowed tumor growth. Peripheral blood of breast 
cancer patients at diagnosis, but not of healthy individuals, contained elevated levels 
of PlGF and circulating proangiogenic CD11b+ myelomonocytes. Taken together our 
results show that cancer cells can program proangiogenic activity in CD11b+ 
myelomonocytes during differentiation of their progenitor cells in a PlGF-dependent 
manner. These findings impact breast cancer biology, detection and treatment. 
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INTRODUCTION 
The formation of new blood vessels within the tumor microenvironment, a process 
known as tumor angiogenesis, promotes tumor growth and metastatic spreading (1, 
2). While newly formed tumor vessels originate mostly by sprouting angiogenesis 
from locally preexisting vessels, increasing evidence indicates that tumor-mobilized 
bone marrow derived (BMD) cells significantly contribute to tumor angiogenesis. Two 
mechanisms have been reported. On the one side tumors mobilize endothelial 
progenitors capable of differentiating into mature endothelial cells and incorporating 
into the nascent tumor endothelium (3). On the other side tumors mobilize myeloid 
cells, which accumulate in the tumor microenvironment and promote tumor 
angiogenesis through paracrine mechanisms (4, 5). A number of elegant studies 
combining cell surface phenotyping, in vivo cell tracing and functional experiments, 
identified multiple angiogenesis-promoting CD11b+ BMD cell populations in mice and 
human (6-11). Little is known, however, on the mechanisms by which tumor-
mobilized CD11b+ myeloid cells are programmed to acquire proangiogenic 
properties. One proposed mechanism is that programming is induced by the tumor 
upon recruitment to the tumor microenvironment (4). Alternatively, programming may 
occur early on during myeloid cell differentiation from hematopoietic progenitors. In 
this work, we have addressed this second hypothesis through experimental studies in 
vitro and in vivo and correlative analyses in cancer patients.  
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MATERIALS AND METHODS 
 
Proteins and chemicals 
Human recombinant PlGF was kindly provided by Prof. Kurt Ballmer, Paul Scherrer 
Institute, Villigen, Switzerland. Human VEGFA, VEGFB, IL8 and IL1β and mouse 
FGF were purchased from PeproTech EC Ltd (London, UK). Human SCF, Flt-3, IL6 
and TPO were purchased from R&D Systems. 4’,6-diamidino-2-phenyl-indole, 
dihydrochloride (DAPI) was purchased from LuBioscience GmbH. Ficoll Histopaque 
Plus 1.077, were from Sigma-Aldrich Chemistry. 
 
Antibodies 
Anti-human antibodies. FITC-conjugated anti-CD11b, anti-CD14, anti-Ki67; PE-
conjugated anti-CD14, PerCP-conjugated anti-CD34; APC-conjugated anti-CD11b; 
Pacific Blue-conjugated anti-CD45 were purchased from BD Pharmingen (Becton 
Dickinson). PE-conjugated anti-Flt-1, APC-conjugated anti-Flt-1, and IgG1 isotype 
control were purchased from R&D Systems. The function-blocking anti-human Flt-1 
antibody KM1732 was described before (12). Anti-mouse antibodies. FITC-
conjugated anti-CD11b; APC-conjugated anti-CD45 were purchased from BD 
Pharmingen (Becton-Dickinson). Unconjugated anti-F4/80 and anti-CD31, PerCP-
conjugated anti-F4/80 and PercP-conjugated rat anti-IgG2a isotype control were 
purchased from Biolegend (San Diego, USA).  
 
Cell lines and primary cells 
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The human breast cancer cell line MDA MB 231 and human non-transformed breast 
epithelium-derived cell line MCF10A were purchased from ATCC (HTB-26D and 
CRL-10317) and cultured in RPMI 1640 medium supplemented with 10% (FCS and 
1% Penicillin/Streptomycin (P/S) (Invitrogen). The primary Human Mammary 
Epithelial Cell (HMEC) line, isolated from normal human breast tissue obtained from 
reduction mammoplasties and the tumorigenic Wnt-1-transformed HMEC line (Wnt-1-
HMEC) were provided by Dr. C. Brisken, ISREC-EPFL, Lausanne (13). Cell 
conditioned medium (CCM, 2 to 4 days old) was collected from cell lines at near-
confluence conditions, filtered at 0.2 m and stored at -20°C. The mouse breast 
cancer cell line 4T1 was provided in 2008 by Dr. Fred R. Miller (Michigan Cancer 
Foundation), Detroit, MI, who originally generated them (14). We have not 
tested/authenticated these cell lines after reception in our laboratory. 4T1 cells were 
cultured in DMEM high glucose supplemented with 10% FCS and 1% P/S. Human 
Umbilical Vein Endothelial Cells (HUVEC) were prepared and cultured as described 
previously (15) and used between passage 3 and 5. BALB/c murine lung endothelial 
cells (MLEC) were generously provided by Dr. K. Hodivala Dilke. CD34+ progenitor 
cells were purified from cord blood using anti-CD34 magnetic beads separation kit 
(StemCell Technologies Inc.) and cultured in RPMI 1640 medium supplemented with 
8% human AB plasma, SCF, Flt-3, IL6 and TPO (basal hematopoietic medium, BHM) 
(16).  
 
Umbilical cord blood 
CD34+ progenitors cells were isolated using EasySep selection kit (stem cells 
technologies) from umbilical cord blood obtained from newborn babies of healthy 
volunteer’s pregnant women for whom a caesarotomy was pre-programmed, upon 
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approval by the ethic committee of the University Hospital of Lausanne (protocol 
236/07) and according to the declaration of Helsinki. 
 
In vitro CD34+ progenitor differentiation assay 
Purified CD34+ cord blood hematopoietic progenitor cells were cultured in a 24-well 
tissue plate in BHM ± 10% filtered CCM from MDA-MB-231, Wnt-1-HMEC, MCF10A, 
HMEC. Cell cultures were harvested at day 7. The morphology of CD11b+ cells 
generated in culture was determined by Wright-Giemsa staining.  
 
Cell sorting  
CD11b+ cells and/or Flt-1+/CD11b+ cells from CD34+-initiated in vitro cultures or from 
PBMC were isolated using EasySep selection kit for labeled cells (Stemcell 
Technologies) or using FACS Aria cell sorting.  
 
In vitro angiogenesis sprouting assay 
HUVEC or MLEC cells were trypsinized and cultured during 24 hours in U bottom 96 
well plates to form spheroids (17) Spheroids were collected and transferred to 1% 
collagen. Cells or cytokines to be tested for angiogenic sprouting activity were added 
on top of the gel. 48 (HUVEC) or 24 (MLEC) hours later sprouting was scored by 
measuring the length of the sprouts using Axiovision Software (Zeiss). Data are 
presented as mean of cumulated sprout lengths from 10 spheroids ± s.d.. 
 
Cytokine measurement 
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Measurements of human or mouse PlGF were performed in duplicate using the 
Quantikine ELISA systems (R&D Systems). Results represent means of duplicate 
determinations ± s.d..  
 
Tumor model 
 4T1 cells were injected (5x104 cells in 50 l PBS/20% Matrigel per injection, 
respectively) in the fourth right inguinal mammary gland of 4-6 week-old BALB/c 
female mice (Harlan or Charles River Laboratories). Tumor growth was measured 
twice a week with a caliper and tumor volume was calculated with the equation: 
volume = /6(length x width2). Single cell suspensions from tumors were obtained as 
recently reported (18). Mouse experiments were approved by the cantonal veterinary 
service of Canton Vaud. 
 
Tumor perfusion measurement by Power Doppler 
Measurements were performed 21 days after tumor cell line injection using the VEVO 
770 micro Three-dimensional High-Frequency Doppler Ultrasound system 
(VisualSonics, Toronto, Canada) equipped with a 30MHz transducer. Mice were 
anesthetized by inhaling a mixture of isoflurane (1.5%) and oxygen (98.5%). The 
anesthetized animals were placed on a warmed examination table, and the tumors 
were covered with ultrasound gel. An ultrasound transducer mounted on a 3D motor 
on a rail system above the animal, moved perpendicular to the beam axis, thereby 
acquiring consecutive two-dimensional images in B mode and power Doppler mode 
with a slice thickness/interval of 500 μm. A region of interest (ROI) was drawn within 
every two-dimensional image. Two-dimensional ultrasound images were used to 
compile a 3D volume using VisualSonic software. Intratumoral perfusion was 
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determined by measuring the Doppler-derived pixels over a constant surface placed 
over the most perfused area of each of three sections per tumor using Image-J free 
software (http://rsbweb.nih.gov/ij/). 5-7 tumors per each experimental condition were 
measured (4T1 wild type, 4T1 non-silenced and 4T1 sh-PlGF). 
 
Corneal angiogenesis assay 
Corneal angiogenesis assay was performed based on a modification of the method 
originally reported (19). CD11b+ cells purified by immunomagnetic beads (Stemcell 
Technologies) were resuspended at 20 x 106 cells/ml in RPMI 1640 medium with 2% 
FCS. NOD/SCID/IL2 receptor common γ2 chain knockout mice were anesthetized 
with ketamine and xylazine and 5μl of cell aliquots were injected into the corneas 
using a 35 gauge nanofil injection kit (WPI). Eyes vascularization was monitored with 
a stereomicroscope and mice were euthanized 20 days post-injection. 
 
Breast cancer patients and healthy donors 
Peripheral blood from healthy donors and cancer patients was obtained according to 
the declaration of Helsinki and upon approval by the ethic committee of the University 
Hospital and University of Lausanne. Breast cancer patients aged from 32 to 75 
years (mean 56.7±13.4) were all previously untreated and presenting at first 
diagnosis with ductal invasive carcinoma without evidence of distant metastasis (T1-
2; N0-1, M0), estrogen receptor positive (85-95%) and scheduled for tumor resection 
(10 patients). Blood was collected the day before surgery. Healthy volunteers were 
individuals without history of cancer, chronic disease or medication other than 
hormonal contraception. PBMCs were isolated using Ficoll-Histopaque Plus (Becton 
Dickinson).  
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Human samples processing 
Blood was collected in Lithium heparin anti-coagulated Vacutainer tubes (Becton 
Dickinson). Plasma phase was collected and centrifuged 5 min at 1500xg at room 
temperature (RT). Plasma was stored at –80°C. PBMC were isolated using Ficoll 
Histopaque Plus 1.077 (25 minutes centrifugation at 680xg at RT). The PBMC 
fraction was collected, washed in PBS, counted, aliquoted at 10x106 cells/mL and 
frozen at -80°C in 90%FCS/10%DMSO medium. 24 hours later, samples are 
transferred into liquid nitrogen.  
 
Statistical analysis  
In all experiments of this study, values are expressed as mean ± 95% confidence 
intervals. Statistical analyses were performed by paired Student's t test unless 
indicated otherwise. Differences were considered statistically significant at p < 0.05.  
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RESULTS 
Breast cancer cell conditioned medium induces the generation of 
proangiogenic CD11b+ myelomonocytic in CD34+ hematopoietic progenitors-
initiated culture 
To test the effect of tumor cells on the generation of proangiogenic CD11b+ myeloid 
cells, we cultured human CD34+ progenitors in a basal hematopoietic medium (BHM) 
(16) alone, or in the presence of culture-conditioned medium (CCM) obtained from 
the tumorigenic metastatic breast cancer-derived cell line MDA-MB-231 or from the 
normal breast epithelium-derived non-tumorigenic cell line MCF-10A. In this model, 
CD34+CD45dull cells progressively disappear to give rise to CD34-CD45dull and CD34-
CD45high populations. CD11b+ cells are present within CD34-CD45high populations 
(>70% CD11b+) and virtually absent from CD34+CD45dull and CD34-CD45dull 
populations (Supplementary Fig. 1A). The CD34-CD45highCD11b+ subpopulation is 
not cycling (Ki67neg) compared to CD11b- populations and has myelomonocytic (non-
macrophage) morphology (Supplementary Fig. 1B and 1C). CD11b+ cells isolated 
from 7 days-old cultures expanded in the presence of MDA-MB-231-derived CCM 
induced robust sprouting in an in vitro endothelial cell-sprouting assay (17), while 
CD11b+ cells isolated from cultures expanded in basal hematopoietic medium (BHM) 
alone or BHM supplemented with MCF-10A-CCM, did not (Fig. 1A). In a second 
experiment, CD11b+ generated from CD34+-initiated cultures exposed to CCM 
derived from normal primary human mammary epithelial cells (HMEC) did not induce 
sprouting, while those exposed to CCM derived from the tumorigenic Wnt-1 
transformed HMEC line (Wnt-1-HMEC) (13) did (Fig. 1B). 
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These results demonstrate that human breast cancer cell lines confer sprouting-
promoting activity to CD11b+ myelomonocytic cells generated from CD34+ 
progenitor-initiated cultures. 
 
Placenta growth factor (PlGF) programs proangiogenic activity in CD11b+ 
myelomonocytic cells derived from CD34+ progenitor-initiated cells cultures 
Several tumor-derived cytokines associated with BMD cell mobilization and 
angiogenesis were expressed in MDA-MB-231 cells (data not shown). Among these 
we tested five for their ability to confer proangiogenic properties to CD11b+ cells: 
VEGF-A, VEGFB, IL8, IL1β, and PlGF. Only CD11b+ cells derived from CD34+-
initiated cultures supplemented with PlGF induced endothelial sprouting (Fig. 2A). 
This effect was not due to a direct effect of PlGF possibly carried over to the 
sprouting assay, since PlGF, in contrast to VEGF, did not induce endothelial 
sprouting even at the highest concentration tested (100 ng/ml) (Supplementary Fig. 
2A). PlGF levels were significantly elevated in CCM of Wnt1-HMEC and MDA-MB-
231 cell lines compared to MCF-10A and HMEC CCM (Supplementary Fig 2B). 
Addition of the function blocking anti-Flt-1 mAb KM1732 (20) and an Flt-1 trap (sFlt-
1-Fc) to CD34+ cell-initiated cultures exposed to MDA-MB-231-derived CCM or PlGF, 
prevented the generation of CD11b+ cells with sprouting-inducing capacity (Fig. 2B 
and supplementary Fig. 2C). CD11b+ cells derived from PlGF and MDA-MB-231-
CCM stimulated cultures induced a robust angiogenic response in vivo in the mouse 
corneal angiogenesis assay, while CD11b+ cells derived form BHM cultures did not 
(Fig. 2C). Addition of PlGF a later time points in CD34+-cell-initiated cultures resulted 
in a progressive decline in the endothelial sprouting activity of generated CD11b+ 
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cells (Supplementary Fig. 3). In CD34+ cell-initiated cultures, Flt-1 was expressed on 
a minority of CD34-/CD45dull/CD11b- cells (≈15-20%) on CD34-/CD45high/CD11b+ 
cells (≈10%), while the majority of CD11b+ cells were negative (Supplementary Fig. 
4). Differentiated Flt-1+CD11b+ cells issued from CD34+ initiated BHM culture and 
further cultured in the presence of PlGF did not acquire proangiogenic activity (Fig. 
2D).  
From these results we conclude that PlGF programs proangiogenic activity in 
CD11b+ myeloid cells during the early stages of differentiation from CD34+ 
hematopoietic progenitors in vitro. 
 
Presence of proangiogenic CD11b+ myeloid cells and elevated levels of PlGF in 
the circulation of breast cancer patients 
These results suggest the possibility that in cancer patients PlGF may program 
CD11b+ myeloid cells to acquire proangiogenic properties while they are generated 
during hematopoiesis. To test whether circulating CD11b+ are proangiogenic, 
CD11b+ myeloid cells were isolated from PBMC collected from the peripheral blood 
of first diagnosed ER+ breast cancer patients (T1-2, N0-1, M0) and healthy donors 
and tested in the endothelial sprouting assay. Indeed, CD11b+ cells isolated from the 
blood of breast cancer patients, but not CD11b+ cells isolated from healthy 
individuals, induced endothelial sprouting in vitro (Fig. 3A). In the same cohort of 
patients we observed significantly increased levels of PlGF compared to healthy 
individuals (Fig. 3B). Exposure of mature CD11b+ myeloid cells isolated from healthy 
donors to PlGF, however, did not result in proangiogenic programming while they did 
after one-week culture in presence of MDA-MB-231 CCM (Supplementary Fig. 5A). 
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Sprouting activity was observed in whole CD11b+ population generated from CD34 
progenitors, but not in Flt-1+CD11b+ cells (supplementary Fig. 5B), and differentiated 
CD11b+ cells were insensitive to PlGF-induced proangiogenic programming (Fig. 
3C).  
These results demonstrate that breast cancer patients have elevated levels of PlGF 
and proangiogenic CD11b+ cells circulating in their blood, compared to healthy 
individuals.  
 
Tumor-derived PlGF promotes proangiogenic programming of CD11b+ 
myelomonocytes and tumor growth 
To test whether PlGF induced proangiogenic programming of CD11b+ 
myelomonocytes in vivo, we silenced PlGF expression in the murine mammary 
carcinoma-derived cell line 4T1 by PlGF shRNA expression (Supplementary Fig. 6A). 
As control 4T1 cells were transduced with a non-silencing shRNA (21), which did not 
affect PlGF expression (Supplementary Fig. 6B). Silencing of PlGF significantly 
lowered plasma PlGF levels in 4T1 tumor-bearing mice (Fig. 4A) and slowed tumor 
growth compared to wild type 4T1 cells or 4T1 cells transduced with the non-
silencing shRNA as measured by tumor volume (Fig. 4B) or weight (Supplementary 
Fig. 7). The frequency of circulating CD11b+ myelomonocytes in 4T1 tumor-bearing 
mice was not affected by PlGF silencing (Fig. 2C). However, circulating CD11b+ cells 
isolated from mice bearing PlGF-silenced tumors did not induce sprouting in an in 
vitro MLEC sprouting assay, compared to CD11b+ cells isolated from control mice 
bearing wild type or non-silenced tumors (Fig. 4D). Importantly, circulating CD11b+ 
cells isolated from the blood of tumor-free mice didn’t induce endothelial sprouting 
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(Supplementary Fig. 6C). PlGF silencing profoundly modified the morphology of the 
tumor vasculature. While in wild type and non-silenced 4T1 tumors the tumor vessels 
were highly heterogeneous, ranging from larger vessels with well-formed lumen to 
microvessels without detectable lumen, in PlGF-silenced tumors vessels were 
uniformly small without detectable lumen (Fig. 5A). Power Doppler analysis revealed 
a significant reduction of blood perfusion in PlGF-silenced 4T1 tumors compared to 
wild type or non-silenced tumors (Fig. 5B). These results are consistent with a 
reduced maturation and functionality of tumor vessels in mice bearing PlGF-silenced 
tumors.  
PlGF silencing did not affect the fraction of F4/80+CD11b+ or F4/80-CD11b+ tumor-
recruited cells (Fig. 5C, Supplementary Fig. 8). (21)Real time RT-PCR analysis of 
selected transcripts encoding for proangiogenic (i.e. VEGF, HBEGF and MMP9) and 
inflammation-modulatory factors (i.e.CCL17, IL10, TNF) in whole tumor explants, 
revealed a down regulation of VEGF, HBVEGF, MMP9, CCL17 and IL10 and an 
upregulation of TNF expression in PlGF-silenced tumors, compared to control 
tumors, consistent with decreased angiogenic activity (Fig. 5D). 
These data demonstrate that in the 4T1 tumor model, silencing of tumor-derived 
PlGF reduces proangiogenic activity of circulating CD11b+ myelomonocytic cells, 
decreases tumor growth, decreases the maturation of the tumor vasculature and 
perfusion and impinges on the production of proangiogenic cytokines in the tumor 
microenvironment.  
 
Metalloproteinase activity is required for sprouting induced by PlGF-
programmed CD11b+ myelomonocytic cells.  
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Next, we searched for factor(s) mediating the endothelial sprouting activity of PlGF-
programmed CD11b+ cells. Endothelial sprouting was still induced when CD11b+ 
cells and endothelial spheroids were physically separated using a transwell system, 
thus implying the involvement of soluble factors (Supplementary Fig. 9A). We 
analyzed the expression of selected candidate genes by real-time RT-PCR in CD34+ 
progenitors-initiated cultures. ITGAM mRNA, the transcript encoding for the CD11b 
protein, was induced in both BHM and PlGF-supplemented cultures. MMP9 mRNA 
was induced 30 to 40-fold by PlGF, while other potentially relevant transcripts (i.e. 
VEGFA, TGFB-1, Sema4D, IF44L, ANG1, or PROK2) were not or only marginally 
affected by PlGF (Fig. 6A). Addition of MMI-270, a synthetic hydroxomate-type MMP 
inhibitors, previously shown to inhibit MMP9 and to suppress tumor angiogenesis 
(22), during the sprouting assay fully blocked endothelial sprouting induced by PlGF-
programmed CD11b+ cells (Fig. 6B). Sprouting induced by VEGF was unaffected 
(Supplementary Fig. 9B). The anti-VEGF blocking antibody bevacizumab caused 
only a minor, statistically non-significant reduction of endothelial cell sprouting 
induced by PlGF-programmed CD11b+ cells (Fig. 9C). Bevacizumab inhibited VEGF-
induced endothelial sprouting, as expected (Supplementary Fig. 9C).  
From these results we conclude that PlGF induces MMP9 expression during 
programming of CD11b+ cells and that metalloproteinase activity is required for 
sprouting activity of PlGF-programmed CD11b+ cells.  
 
16
ht
tp
://
do
c.
re
ro
.c
h
Proangiogenic programming of CD11b+ cells by PlGF
DISCUSSION  
Different myeloid cell subsets with proangiogenic and tumor-promoting properties 
have been recently reported, including VEGFR1+CD11b+ cells (8), VEGFR-
1+CXCR4+CD11b+ cells (6, 7), Gr1+CD11b+ cells (9), and Tie-2+CD11b+ monocytes 
(23). While it is well accepted that CD11b+ cells and subsets thereof promote tumor 
angiogenesis once recruited at tumor sites (12), the question of whether 
proangiogenic education may already occur during CD11b+ myeloid cell generation 
from progenitors has not been formally addressed. Here we provide experimental 
and clinical evidence demonstrating that breast cancer can program CD11b+ myeloid 
cells to acquire proangiogenic activity while differentiating from CD34+ hematopoietic 
progenitors though a PlGF-dependent mechanism, and that proangiogenic CD11b+ 
cells circulate in the blood of tumor-bearing mice and cancer patients. While blood-
circulating TEM in tumor-bearing mice were reported to stimulate tumor angiogenesis 
when co-injected together with tumor cells in mice (24), we demonstrate for the first 
time that circulating CD11b+ monocytes in tumor-bearing mice and breast cancer 
patients induce endothelial cell sprouting. PlGF only programs myeloid cells while 
they differentiate from progenitor cells. It is unable to program differentiated CD11b+ 
cells even if expressing Flt-1, while tumor cell-derived conditioned medium does. 
These results suggest that further angiogenic programming of CD11b+ cells might 
occur upon recruitment to the tumor microenvironment.  
Two important corollaries stem from these observations. First, endothelial cell 
sprouting-inducing activity of circulating CD11b+ cells might be potential biomarker of 
angiogenesis (25). Second, circulating CD11b+ monocytes possessing proangiogenic 
capacity and homing to normal tissues (e.g. lung and bone) might promote metastatic 
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spreading by facilitating initial angiogenesis and thereby contributing to tumor cell 
extravasation and formation of the pre-metastatic niche (26, 27). A translational study 
aimed at testing these hypotheses is currently in progress in our breast cancer clinic.  
Cumulating evidence point to a role of PlGF in promoting human cancer progression, 
including breast cancer. PlGF expression is increased in breast cancer tissues 
compared to normal breast and elevated PlGF levels are associated with elevated 
risk for recurrence, metastasis and reduced survival (28, 29). Elevated levels of PlGF 
also correlate with progression and reduced survival in mesothelioma (30), oral (31), 
non-small cell lung (32), colon (33), renal (34), brain (35), hepatocellular (36) and 
gastric (37) cancers. Genetic ablation of PlGF or antibody-based PlGF inhibition 
suppressed tumor angiogenesis and tumor growth and enhanced efficacy of anti-
VEGF therapy (38-40). The angiogenic activity of PlGF appears indirect and 
mediated by bone marrow derived myeloid cells recruited to sites of angiogenesis 
(39, 41). Recently the role of PlGF in promoting tumor-angiogenesis has been 
challenged by a report (42) in which new anti-PlGF antibodies failed to suppress 
tumor angiogeneis. By demonstrating that PlGF programs proangiogenic activity in 
differentiating CD11b+ cells, we provide further evidence for its role in cancer (38, 
41). 
Furthermore, we identified MMP9 as being strongly upregulated by PlGF and show 
that MMP inhibition suppresses the proangiogenic activity of programmed CD11b+ 
cells. MMP9 it thought to promote angiogenesis through the release of matrix-bound 
VEGF at tumor sites (43) and by mobilizing BMD cells (44). MMP9 is also induced by 
primary tumors in an Flt-1-dependent manner in endothelial cells and macrophages 
at premetastatic sites in the lung (45). Whether MMP9 expression in the lungs was 
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due a PlGF-mediated angiogenic programming and recruitment of monocytes was 
not addressed in that study. Thus, our results provide experimental evidence for a 
functional link between PlGF, MMP9 expression during proangiogenic programming 
of CD11b+ cells and requirement of MMP activity in promoting endothelial sprouting.  
Taken together, our work unravels a previously unrecognized activity of PlGF, 
namely the proangiogenic programming of differentiating CD11b+ myelomonocytic 
cells, with relevant implications to breast cancer biology, detection and treatment and 
reinforces published observations on the contribution of the PlGF/Flt-1 axis in cancer 
progression.  
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FIGURE LEGENDS 
 
Figure 1. Conditioned medium from breast cancer cell cultures programs 
proangiogenic activity in CD11b+ myelomonocytic cells differentiating from CD34+ 
progenitors. A Endothelial sprouting activity of CD11b+ cells isolated from CD34+ 
hematopoietic progenitor-initiated cultures expanded in the presence of basal 
hematopoietic medium (BHM) or BHM supplemented with cell culture medium (CCM) 
conditioned by MCF-10A (normal breast epithelium-derived) or MDA-MB-231 (breast 
cancer-derived) cells. B, Endothelial sprouting activity of CD11b+ cells isolated from 
CD34+ hematopoietic progenitor-initiated cultures expanded in the presence of BHM 
or BHM supplemented with CCM derived from HMEC (normal breast epithelium-
derived) primary cells or Wnt-1 transformed HMEC cell cultures (Wnt-1-HMEC). Only 
CCM derived from tumor cell lines induced angiogenic programming of CD11b+ cells. 
CSL: cumulative sprout length. Bar graphs represent mean values and standard 
deviations (95% confidence intervals). 
 
Figure 2. PlGF programs angiogenic activity in CD11b+ myelomonocytic cells 
differentiating from CD34+ progenitors. A, Endothelial sprouting activity of CD11b+ 
cells isolated from CD34+ hematopoietic progenitor-initiated cultures in the presence 
of basal hematopoietic medium (BHM) alone or BHM supplemented with 
recombinant VEGFA, VEGFB, IL1β, IL8 or PlGF. Only PlGF induced proangiogenic 
programming. B, Flt-1 function-blocking mAb KM1732 and Flt-1 trap (sFlt-1–Fc) 
26
ht
tp
://
do
c.
re
ro
.c
h
Proangiogenic programming of CD11b+ cells by PlGF
inhibited angiogenic programming of CD11b+ cells derived from CD34+ hematopoietic 
progenitors-initiated cultures stimulated with PlGF or MDA-MB-231 CCM (CCM-
MDA). C, In vivo corneal angiogenesis assay. CD11b+ cells generated in vitro from 
CD34+ hematopoietic progenitors in the presence of BHM, MDA-MB-231 CCM or 
recombinant PlGF were injected into the mouse cornea. Angiogenic response was 
evaluated 20 days later. Cells exposed to MDA-MB-231 CCM or PlGF, but not BHM, 
induced cornea angiogenesis. D, Angiogenic programming of mature CD11b+ cells. 
CD11b+ cells generated from BHM-CD34+ cultures were further cultivated for 4 days 
in the absence or presence of PlGF and their proangiogenic activity was determined 
in comparison to CD11b+ cells generated from CD34+ initiated culture in the 
continuous presence of PlGF. PlGF did not program differentiated CD11b+ cells. 
CSL: cumulative sprout lengths. Bar graphs represent mean values and standard 
deviations (95% confidence intervals). 
 
Figure 3. Peripheral blood CD11b+ myeloid cells in breast cancer patients are 
proangiogenic. A, Micrographs and quantification of angiogenic sprouting activity of 
CD11b+ cells isolated from the peripheral blood of healthy donor (HD) (n=10) and 
non-metastatic breast cancer (BC) patients (n=10). BC-, but not HD-derived, CD11b+ 
cells promoted endothelial sprouting. B, Elevated levels of plasma PlGF was 
observed in non-metastatic breast cancer (BC) patients compared to healthy donors 
(HD). C, CD11b+ cells isolated from peripheral blood of HD and cultured for 4 
additional days in the presence of basal hematopoietic medium (BHM) or BHM-PlGF 
do not acquire proangiogenic activity (n=3). VEGF: induction of sprouting by addition 
of recombinant VEGFA during the sprouting assay. CSL: cumulative sprout lengths. 
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Bar graphs represent mean values and standard deviations (95% confidence 
intervals). 
 
Figure 4. PlGF silencing abrogates the proangiogenic properties of circulating 
CD11b+ myelomonocytes in 4T1 tumor bearing mice. A, Plasma levels of PlGF in 
BALB/c mice bearing orthotopic tumors derived from parental (4T1), non-silenced 
(NS) and PlGF-silenced 4T1 cells (shPlGF). Mice bearing PlGF-silenced 4T1 tumors 
have significantly reduced plasma PlGF levels. B, PlGF silencing inhibits 4T1 tumor 
growth. The volume of tumors derived from parental (4T1), non-silenced (NS) and 
PlGF-silenced 4T1 cells (shPlGF) was measured clinically at the indicated days. 
Representative volumes of 3 tumors measured by ultrasound are illustrated in a 3D 
reconstitution. C, Frequency of CD11b+ cells measured by flow cytometry in the 
peripheral blood of tumor-bearing BALB/c mice at day 17 days after tumor cell 
injection. D, Tumor-derived PlGF programs proangiogenic activity in CD11b+ cells in 
vivo. CD11b+ cells isolated from peripheral blood of tumor-bearing BALB/c mice 17 
days after tumor cell injection, were tested in the sprouting assay. CD11b+ cells 
derived from mice bearing PlGF-silenced 4T1 tumors did not induce endothelial 
sprouting. 4T1, Wild type; NS, non-silenced 4T1 cells; shPlGF 4T1, PlGF-silenced 
4T1 cells. 
 
Figure 5. PlGF silencing inhibits 4T1 tumor growth and perfusion and decreases the 
production of proangiogenic cytokines in the tumor microenvironment. A, CD31 and 
F4/80 immunohistochemistry staining of tumor biopsies from tumor-bearing BALB/c 
mice 21 days after tumor cell injection. PlGF-silenced tumors lack vessels with 
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lumen. Endothelial cell surface and vessels with lumen were quantified (lower 
panels). B, Power Doppler-based perfusion analysis of orthotopically implanted 
tumors in BALB/c mice. The images show an ultrasonographic tumor cross section 
(black and white) overlaid with the perfusion signal (color). PlGF silencing in 4T1 
tumors decreased tumor perfusion. C, Frequency of F4/80+CD11b+ cells within 
CD45+ cells recovered from tumors and analyzed by flow cytometry 17 days after 
tumor injection (upper panel). Dot plot representation of CD11b+ versus F4/80+ cells 
in a wild type tumor (lower panel). Infiltrating CD11b+ cells are F4/80+/-. D, PlGF 
silencing modulates expression of the angiogenic factors VEGFA, HBEGF, and 
MMP9 and proinflammatory cytokines CCL17, IL10 and TNF in whole tumors. mRNA 
was measured by real time RT-PCR. Bar graphs represent mean values and 
standard deviations (95% confidence intervals). 4T1, Wild type; NS, non-silenced 
4T1; shPlGF 4T1, PlGF-silenced 4T1 cells. 
 
Figure 6. Metalloproteinase activity is required for sprouting activity in PlGF-
programmed CD11b+ myelomonocytic cells. A, Expression of ITGAM, TGFB-1, 
SEMA4D, IF44L, ANG1, MMP9, VEGFA and PROK2 mRNA in CD34+ hematopoietic 
progenitors-initiated cultures was monitored by real time RT-PCR. PlGF induced 
MMP9 expression compared to BHM cultures. The time course is coded by gray 
shading of the bars (day 2 to 7 from left to right). B, The MMP inhibitor MMI-270 
inhibited endothelial cell sprouting activity induced by PlGF-programmed CD11b+ 
cells. C) The anti-VEGFA antibody bevacizumab (BV) added during the sprouting 
assay did not inhibit endothelial sprouting induced by PlGF-educated CD11b+ cells. 
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CSL: cumulative sprout lengths. Bar graphs represent mean values and standard 
deviations (95% confidence intervals). 
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